China Medical System Holdings Limited (0867.HK)
HKD 7.36
(-0.67%)
HKD 7.36
(-0.67%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 8.01 Billion CNY | -12.43% |
| 2022 | 9.15 Billion CNY | 9.75% |
| 2021 | 8.33 Billion CNY | 20.03% |
| 2020 | 6.94 Billion CNY | 14.36% |
| 2019 | 6.07 Billion CNY | 11.78% |
| 2018 | 5.43 Billion CNY | 1.58% |
| 2017 | 5.34 Billion CNY | 9.14% |
| 2016 | 4.9 Billion CNY | 37.92% |
| 2015 | 3.55 Billion CNY | 20.65% |
| 2014 | 2.94 Billion CNY | 33.78% |
| 2013 | 2.2 Billion CNY | 25.13% |
| 2012 | 1.75 Billion CNY | 33.05% |
| 2011 | 1.32 Billion CNY | 50.83% |
| 2010 | 876.67 Million CNY | 33.12% |
| 2009 | 658.58 Million CNY | 32.93% |
| 2008 | 495.42 Million CNY | 31.06% |
| 2007 | 378.01 Million CNY | 28.79% |
| 2006 | 293.52 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.8 Billion CNY | 6.11% |
| 2024 Q2 | 1.8 Billion CNY | 0.0% |
| 2023 Q1 | 2.3 Billion CNY | -1.97% |
| 2023 FY | 8.01 Billion CNY | -12.43% |
| 2023 Q4 | 1.7 Billion CNY | 0.0% |
| 2023 Q3 | 1.7 Billion CNY | -26.18% |
| 2023 Q2 | 2.3 Billion CNY | 0.0% |
| 2022 Q1 | 2.22 Billion CNY | -1.03% |
| 2022 FY | 9.15 Billion CNY | 9.75% |
| 2022 Q4 | 2.35 Billion CNY | 0.0% |
| 2022 Q3 | 2.35 Billion CNY | 5.73% |
| 2022 Q2 | 2.22 Billion CNY | 0.0% |
| 2021 Q3 | 2.24 Billion CNY | 16.94% |
| 2021 FY | 8.33 Billion CNY | 20.03% |
| 2021 Q1 | 1.92 Billion CNY | 0.13% |
| 2021 Q4 | 2.24 Billion CNY | 0.0% |
| 2021 Q2 | 1.92 Billion CNY | 0.0% |
| 2020 Q3 | 1.91 Billion CNY | 23.48% |
| 2020 FY | 6.94 Billion CNY | 14.36% |
| 2020 Q1 | 1.55 Billion CNY | -0.04% |
| 2020 Q2 | 1.55 Billion CNY | 0.0% |
| 2020 Q4 | 1.91 Billion CNY | 0.0% |
| 2019 Q1 | 1.48 Billion CNY | 6.69% |
| 2019 Q3 | 1.55 Billion CNY | 4.89% |
| 2019 Q4 | 1.55 Billion CNY | 0.0% |
| 2019 FY | 6.07 Billion CNY | 11.78% |
| 2019 Q2 | 1.48 Billion CNY | 0.0% |
| 2018 Q2 | 1.32 Billion CNY | 0.0% |
| 2018 Q4 | 1.38 Billion CNY | 0.0% |
| 2018 FY | 5.43 Billion CNY | 1.58% |
| 2018 Q1 | 1.32 Billion CNY | -0.28% |
| 2018 Q3 | 1.38 Billion CNY | 4.65% |
| 2017 Q1 | 1.34 Billion CNY | -1.37% |
| 2017 FY | 5.34 Billion CNY | 9.14% |
| 2017 Q4 | 1.33 Billion CNY | 0.0% |
| 2017 Q3 | 1.33 Billion CNY | -0.89% |
| 2017 Q2 | 1.34 Billion CNY | 0.0% |
| 2016 FY | 4.9 Billion CNY | 37.92% |
| 2016 Q1 | 1.08 Billion CNY | 15.99% |
| 2016 Q2 | 1.08 Billion CNY | 0.0% |
| 2016 Q3 | 1.36 Billion CNY | 25.11% |
| 2016 Q4 | 1.36 Billion CNY | 0.0% |
| 2015 Q4 | 938.51 Million CNY | 0.0% |
| 2015 FY | 3.55 Billion CNY | 20.65% |
| 2015 Q2 | 838.2 Million CNY | 0.0% |
| 2015 Q1 | 838.2 Million CNY | 6.21% |
| 2015 Q3 | 938.51 Million CNY | 11.97% |
| 2014 Q2 | 683.36 Million CNY | 0.0% |
| 2014 Q1 | 683.36 Million CNY | 13.12% |
| 2014 FY | 2.94 Billion CNY | 33.78% |
| 2014 Q4 | 789.19 Million CNY | 0.0% |
| 2014 Q3 | 789.19 Million CNY | 15.49% |
| 2013 Q3 | 604.13 Million CNY | 16.1% |
| 2013 Q4 | 604.13 Million CNY | 0.0% |
| 2013 FY | 2.2 Billion CNY | 25.13% |
| 2013 Q1 | 520.36 Million CNY | 11.44% |
| 2013 Q2 | 520.36 Million CNY | 0.0% |
| 2012 FY | 1.75 Billion CNY | 33.05% |
| 2012 Q2 | - CNY | -100.0% |
| 2012 Q1 | 512.57 Million CNY | 0.0% |
| 2012 Q3 | 471.01 Million CNY | 0.0% |
| 2012 Q4 | 466.95 Million CNY | -0.86% |
| 2011 Q2 | - CNY | 0.0% |
| 2011 FY | 1.32 Billion CNY | 50.83% |
| 2011 Q4 | - CNY | 0.0% |
| 2010 FY | 876.67 Million CNY | 33.12% |
| 2010 Q4 | - CNY | 0.0% |
| 2010 Q2 | - CNY | 0.0% |
| 2009 FY | 658.58 Million CNY | 32.93% |
| 2008 FY | 495.42 Million CNY | 31.06% |
| 2007 FY | 378.01 Million CNY | 28.79% |
| 2006 FY | 293.52 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -2992.046% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 23.897% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -13459.317% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -922.258% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | -733.596% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | -660.971% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | -369.559% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -890.386% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -1869.548% |
| SSY Group Limited | 6.46 Billion HKD | -23.987% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -1135.827% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | -445.939% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 97.036% |